INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Nov 30, 2012 |
SVP Res and Devel Sciences
|
SVP Res and Devel Sciences | Form 4 | Open market or private sale of non-derivative or derivative security | 17,182 | $181.01 | 41,939 |
| Nov 14, 2011 |
SVP Research and Development S
|
SVP Research and Development S | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 17,182 | $11.64 | 67,532 |
| Nov 14, 2011 |
SVP Research and Development S
|
SVP Research and Development S | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 17,182 | -- | -- |
| Dec 19, 2005 |
SVP, PreclinDevel & Biomol Sci
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 17,182 | -- | 17,182 |
| Dec 09, 2020 |
EVP Research and Development
|
EVP Research and Development | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 17,500 | -- | 17,500 |
| Feb 14, 2012 |
SVP Research and Development S
|
SVP Research and Development S | Form 4 | Open market or private sale of non-derivative or derivative security | 17,694 | $110.35 | 82,518 |
| Aug 06, 2014 |
SVP Research and Development S
|
SVP Research and Development S | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 18,301 | $336.11 | 28,014 |
| Oct 31, 2006 |
SVP, Therap & Clin Prog Dev
|
SVP, Therap & Clin Prog Dev | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 18,311 | $10.56 | 22,198 |
| Oct 31, 2006 |
SVP, Therap & Clin Prog Dev
|
SVP, Therap & Clin Prog Dev | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 18,311 | -- | -- |
| Feb 15, 2012 |
SVP Research and Development S
|
SVP Research and Development S | Form 4 | Open market or private sale of non-derivative or derivative security | 19,057 | $107.79 | 61,146 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.